Literature DB >> 16243384

Arsenic Trioxide inhibits the growth of human ovarian carcinoma cell line.

Jacob Bornstein1, Shlomi Sagi, Amer Haj, Jeffrey Harroch, Fuad Fares.   

Abstract

OBJECTIVE: To determine whether Arsenic Trioxide may be an effective treatment of human ovarian carcinoma, we examined if it induced apoptosis in human ovarian cancer cell line.
METHODS: The human ovarian cell line SKOV3 was exposed to different concentrations of As2O3: 0 (control), 0.1 microM, 1 microM, 5 microM and 10 microM. The effect on cells proliferation and apoptotic parameters was examined.
RESULTS: The most effective inhibitory Arsenic Trioxide concentrations were 5 microM and 10 microM, causing growth inhibition of 79% and 83%, respectively. The maximum inhibitory effect of Arsenic Trioxide on cellular proliferation was seen after 48 h. No morphological or molecular features of apoptosis have been observed. At the same time, there were no typical changes of cellular necrosis.
CONCLUSIONS: The exact mechanism by which Arsenic Trioxide inhibits the growth of ovarian cancer cells is probably not by apoptosis. However, since As2O3 has been shown to inhibit ovarian cancer cellular growth, it should be further elucidated as a possible chemotherapeutic agent of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16243384     DOI: 10.1016/j.ygyno.2005.07.125

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  9 in total

1.  Developmental and genetic modulation of arsenic biotransformation: a gene by environment interaction?

Authors:  Mercedes Meza; A Jay Gandolfi; Walter T Klimecki
Journal:  Toxicol Appl Pharmacol       Date:  2006-12-23       Impact factor: 4.219

2.  The conformation change of Bcl-2 is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in SGC7901 human gastric cancer cells.

Authors:  Yihu Zheng; Mengtao Zhou; Aifang Ye; Qiu Li; Yongheng Bai; Qiyu Zhang
Journal:  World J Surg Oncol       Date:  2010-04-20       Impact factor: 2.754

3.  Arsenic trioxide induces a beclin-1-independent autophagic pathway via modulation of SnoN/SkiL expression in ovarian carcinoma cells.

Authors:  D M Smith; S Patel; F Raffoul; E Haller; G B Mills; M Nanjundan
Journal:  Cell Death Differ       Date:  2010-05-28       Impact factor: 15.828

4.  BIM-mediated AKT phosphorylation is a key modulator of arsenic trioxide-induced apoptosis in cisplatin-sensitive and -resistant ovarian cancer cells.

Authors:  Zhu Yuan; Fang Wang; Zhiwei Zhao; Xinyu Zhao; Ji Qiu; Chunlai Nie; Yuquan Wei
Journal:  PLoS One       Date:  2011-05-31       Impact factor: 3.240

5.  Enhancing the efficacy of cisplatin in ovarian cancer treatment - could arsenic have a role.

Authors:  C William Helm; J Christopher States
Journal:  J Ovarian Res       Date:  2009-01-14       Impact factor: 4.234

6.  Downregulation of P-gp, Ras and p-ERK1/2 contributes to the arsenic trioxide-induced reduction in drug resistance towards doxorubicin in gastric cancer cell lines.

Authors:  Yuan-Yuan Zhao; Li Yu; Bao-Ling Liu; Xin-Jia He; Bi-Yuan Zhang
Journal:  Mol Med Rep       Date:  2015-09-25       Impact factor: 2.952

7.  1,2-Benzenedithiol and Toluene-3,4-dithiol Arsenic(III) Complexes-Synthesis, Structure, Spectroscopic Characterization and Toxicological Studies.

Authors:  Monika Lyczko; Krzysztof Lyczko; Agnieszka Majkowska-Pilip; Aleksander Bilewicz
Journal:  Molecules       Date:  2019-10-26       Impact factor: 4.411

8.  Integrative network analysis identifies potential targets and drugs for ovarian cancer.

Authors:  Tianyu Zhang; Liwei Zhang; Fuhai Li
Journal:  BMC Med Genomics       Date:  2020-09-21       Impact factor: 3.063

Review 9.  Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer.

Authors:  Maritza P Garrido; Allison N Fredes; Lorena Lobos-González; Manuel Valenzuela-Valderrama; Daniela B Vera; Carmen Romero
Journal:  Biomedicines       Date:  2021-12-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.